Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer

Diagnostic Pathology

Shiwei Duan⁴  Meng Ye²  Leiting Xu⁴  Fei Chen⁴  Huadan Ye⁴  Yi Huang³  Qi Liao⁴  Lingyan Wang¹  Cheng Chen² 

[1] Bank of Blood Products, Ningbo No.2 Hospital, Ningbo, Zhejiang 315010, China;The Affiliated Hospital, Ningbo University, Ningbo, Zhejiang 315000, China;Department of Neurosurgery, Ningbo First Hospital, Ningbo University, Ningbo, Zhejiang 315010, China;Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China

关键词: Biomarker;    DNA methylation;    EDNRB;    Colorectal cancer;   

Others  :  803826
DOI  :  10.1186/1746-1596-8-199

 received in 2013-10-22, accepted in 2013-12-06,  发布年份 2013

【 摘 要 】

Objective

Colorectal cancer (CRC) is one of the most common digestive malignancies in the world. EDNRB is a new candidate tumor suppressor gene which is often down-regulated or even silenced by promoter hypermethylation in various human cancers. However, the function of EDNRB gene in CRC remains unknown. In this study, we examined the expression and DNA methylation of EDNRB in CRC tissues.

Methods

A total of 42 paired CRC and adjacent normal tissue samples were used to determine mRNA levels and DNA methylation status of EDNRB gene by qRT-PCR and methylation-specific PCR (MSP), respectively.

Results

Our study showed that EDNRB promoter hypermethylation was more frequently in CRC tissues than in the normal tissues (92.86 versus 59.52, p = 0.001). Consequently, significantly lower level of EDNRB mRNA was found in CRC tumor samples than in normal samples (0.31 ± 0.91 versus 0.70 ± 1.18, p = 0.032).

Conclusions

Our results suggested that EDNRB promoter hypermethylation might downregulate its gene expression in CRC, and thus played an important role in the development of CRC.

The virtual slide

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7420980471113303 webcite

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Migliore L, Migheli F, Spisni R, Coppede F: Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011, 2011:792362.
• [2]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
• [3]Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al.: Colon cancer. Crit Rev Oncol Hematol 2010, 74(2):106-133.
• [4]Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J: Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol 2013, 8:10. BioMed Central Full Text
• [5]Nodin B, Johannesson H, Wangefjord S, O’Connor DP, Lindquist KE, Uhlen M, et al.: Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol 2012, 7:115. BioMed Central Full Text
• [6]Dekanic A, Dintinjan RD, Budisavljevic I, Pecanic S, Butorac MZ, Jonjic N: Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol 2011, 6:108. BioMed Central Full Text
• [7]Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y: Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 2009, 11(2):143-149.
• [8]Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, Yanagisawa M, et al.: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung’s disease. Cell 1994, 79(7):1257-1266.
• [9]Eberle J, Weitmann S, Thieck O, Pech H, Paul M, Orfanos CE: Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 1999, 112(6):925-932.
• [10]Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones PA: The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001, 10(9):903-910.
• [11]Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, et al.: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66(10):5495-5503.
• [12]Hsiao PC, Liu MC, Chen LM, Tsai CY, Wang YT, Chen J, et al.: Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan. Chin J Physiol 2008, 51(1):27-31.
• [13]Schussel J, Zhou XC, Zhang Z, Pattani K, Bermudez F, Jean-Charles G, et al.: EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res 2013, 19(12):3268-3275.
• [14]Zhang M, Song F, Liang L, Nan H, Zhang J, Liu H, et al.: Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. Hum Mol Genet 2013, 22(14):2948-2959.
• [15]Roh JL, Wang XV, Manola J, Sidransky D, Forastiere AA, Koch WM: Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study. Clin Cancer Res 2013, 19(9):2528-2540.
• [16]Cruz-Munoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, et al.: Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res 2012, 72(19):4909-4919.
• [17]Wuttig D, Zastrow S, Fussel S, Toma MI, Meinhardt M, Kalman K, et al.: CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 2012, 131(5):E693-E704.
• [18]Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al.: A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int 2012, 109(6):941-948.
• [19]Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al.: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011, 30(4):151-161.
• [20]de Freitas C-SM, Oliveira ZF, de Podesta JR, Gouvea SA, Von Zeidler SV, Louro ID: Methylation analysis of cancer-related genes in non-neoplastic cells from patients with oral squamous cell carcinoma. Mol Biol Rep 2011, 38(8):5435-5441.
• [21]Tang W, Li B, Tang J, Liu K, Qin J, Wu W, et al.: Methylation analysis of EDNRB in human colon tissues of Hirschsprung’s disease. Pediatr Surg Int 2013, 29(7):683-688.
• [22]Shen WJ, Dai DQ, Teng Y, Liu HB: Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol 2008, 14(4):595-600.
• [23]Du YY, Dai DQ, Yang Z: Role of RECK methylation in gastric cancer and its clinical significance. World J Gastroenterol 2010, 16(7):904-908.
• [24]Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK: Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol 2011, 137(8):1255-1262.
• [25]Kang GH, Lee S, Kim JS, Jung HY: Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83(5):635-641.
• [26]Tost J: DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol 2010, 44(1):71-81.
• [27]Davenport AP, Maguire JJ: Endothelin. Handb Exp Pharmacol 2006, 176(1):295-329.
• [28]Zhao BJ, Sun DG, Zhang M, Tan SN, Ma X: Identification of aberrant promoter methylation of EDNRB gene in esophageal squamous cell carcinoma. Dis Esophagus 2009, 22(1):55-61.
• [29]Lahav R, Heffner G, Patterson PH: An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999, 96(20):11496-11500.
• [30]Mallat A, Fouassier L, Preaux AM, Gal CS, Raufaste D, Rosenbaum J, et al.: Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest 1995, 96(1):42-49.
• [31]Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3(2):110-116.
• [32]Tao K, Wu C, Wu K, Li W, Han G, Shuai X, et al.: Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer. Med Oncol 2012, 29(1):107-112.
• [33]Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al.: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64(6):1975-1986.